These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 9561346)

  • 1. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
    Coukell AJ; Brogden RN
    Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children.
    Tollemar J; Klingspor L; Ringdén O
    Clin Microbiol Infect; 2001; 7 Suppl 2():68-79. PubMed ID: 11525221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.
    Ng TT; Denning DW
    Arch Intern Med; 1995 May; 155(10):1093-8. PubMed ID: 7748054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal amphotericin B, AmBisome.
    Hay RJ
    J Infect; 1994 May; 28 Suppl 1():35-43. PubMed ID: 8077689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children.
    Ringdén O; Tollemar J
    Mycoses; 1993; 36(5-6):187-92. PubMed ID: 8264715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
    Viscoli C; Castagnola E
    Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.
    Ringdén O; Meunier F; Tollemar J; Ricci P; Tura S; Kuse E; Viviani MA; Gorin NC; Klastersky J; Fenaux P
    J Antimicrob Chemother; 1991 Oct; 28 Suppl B():73-82. PubMed ID: 1778894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B.
    Chen SC;
    J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():57-61. PubMed ID: 11801583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
    Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
    J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
    Blyth CC; Hale K; Palasanthiran P; O'Brien T; Bennett MH
    Cochrane Database Syst Rev; 2010 Feb; 2010(2):CD006343. PubMed ID: 20166083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-based formulations of amphotericin B.
    Veerareddy PR; Vobalaboina V
    Drugs Today (Barc); 2004 Feb; 40(2):133-45. PubMed ID: 15045035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M; Letscher-Bru V; Herbrecht R
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B in neonates with invasive candidiasis.
    Al Arishi H; Frayha HH; Kalloghlian A; Al Alaiyan S
    Am J Perinatol; 1998; 15(11):643-8. PubMed ID: 10064206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients.
    Chopra R; Blair S; Strang J; Cervi P; Patterson KG; Goldstone AH
    J Antimicrob Chemother; 1991 Oct; 28 Suppl B():93-104. PubMed ID: 1778896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
    Cordonnier C; Bresnik M; Ebrahimi R
    Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
    Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
    Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.